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INTRODUCTION 
Sickle cell disease is one of the most frequently occurring 
hereditary conditions. Since 1949, when Pauling et al (l) des¬ 
cribed a different mobility of sickle hemoglobin on electrophoresis, 
much has been learned about the molecular structure of normal and 
abnormal hemoglobins. However, at the present time, relatively 
little is known about the pathophysiology of the clinical manifesta¬ 
tions of the disease. 
It is believed that the physical properties of the reduced Hb S 
molecule account for most of the clinical manifestations of sickle 
cell disease. Linear orientation of sickle hemoglobin molecules in 
the deoxygenated state is considered to be the cause of the sickle 
cell deformity. Factors which are known to cause linear polymer 
formation, and in turn, sickling of cells include low levels of 
oxygen tension (2), a drop in pH (3), and hypertonicity of the sur¬ 
rounding medium (4). The physiologic consequences of such changes 
are an increased blood viscosity secondary to clumping of sickled 
cells and resultant damage to the microvasculature. The actual 
clinical features of the disease may be related to these phenomena. 
Since the medullary area of the kidney is the site of generation of 
low pH and high osmolality, and possesses a low oxygen tension, it 
is not surprising that patients with sickle cell disease have sig¬ 
nificant, progressive impairment of renal function. The purpose 
of this study was to investigate renal tubular function in patients 
with sickle cell disease, with particular emphasis on their ability 
to excrete potassium. 
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LITERATURE REVIEW 
Anatomical Changes 
An understanding of the renal ma.nifestations of sickle cell 
disease may be gained by reviewing the anatomical changes observed 
in the kidneys of such patients. 
The most consistent finding on microscopic examination of the 
glomeruli of the kidneys of sickle cell patients is overall enlarge¬ 
ment, with dilatation of glomerular capillaries (5). Bernstein 
and Whitten (i960) examined fifteen autopsy cases of children (ages 
1-15 years) wich sickle cell disease. In those children under 
the age of two the glomeruli appeared normal except for mild vascular 
congestion and dilatation of the vascular loops. In the older 
children the glomeruli were more congested with striking glomerular 
enlargement, particularly of the juxtamedullary glomeruli. This 
enlargement was due primarily to an increase in glomerular vascu¬ 
larity. Focal areas of ischemia and fibrosis were common. Pitcock 
et al (6) reported on renal biopsies performed on patients 17 to 27 
years of age who had Hb SS but no evidence of clinical renal disease 
except for a urinary concentrating defect. They noted stainable 
iron in the glomerular epithelial cells of both parietal and visceral 
type, usually in association with an increase in mesangial matrix, 
and with electron dense material in mesangial cells. In some cases 
there was focal fusion of foot processes and occasional small granu¬ 
lar deposits in glomerular basement membrane. The significance of 
these findings are questionable, however, since most evidence sug¬ 
gests that patients with sickle cell disease rarely develop proteinuria, 

the nephrotic syndrome, or progressive glomerulonephritis (?). 
There are occasional reports of the presence of the nephrotic 
syndrome in patients with sickle cell disease. However, it has not 
always b :en possible to exclude other etiologic factors in these 
cases. McCoy (8) studied three patients with nephrotic syndrome who 
were found to have electron-dense deposits in the mesangium and 
glomerular basement membrane. He found that these deposits stained 
for iron, and he postulated that they represented protein-iron com¬ 
plexes originating in the circulation that had been phagocytized 
by glomerular mesangial cells. He further postulated that these 
complexes were responsible for the development of the nephrotic 
syndrome. Walker (9) studied renal biopsy specimens of SS patients. 
Four had normal renal function studies, 3 had proteinuria, 2 had 
uremia. Some of the specimens he reviewed had lesions indistinguish¬ 
able from those of a proliferative glomerulonephritis, however, the 
patient with the lowest creatinine clearance in his group had norma], 
glomeruli suggesting that in these patients renal function tests 
did not reflect the degree of pathological glomerular disease. 
More recently, Pardo et al (lO) rnported an immune complex 
glomerulonephritis in seven patients with sickle cell anemia and 
proteinuria. One or more findings of the nephrotic syndrome, hyper¬ 
tension, hematuria, and renal insufficiency were found in more than 
half of the patients. All patients had membranoproliterative glom¬ 
erulonephritis of varying degree. Immanoflourescent studies revealed 
IgG and 03 in a granular pattern along the basement membrane and the' 
mesangium of all patients studied. Renal tubular antigen was 
localized in the same pattern as immunoglobulins and C3 in two of 
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the subjects studied. On the basis of these findings, these authors 
suggested that the membranoproliferative glomerulonephritis associated 
with sickle cell anemia is a result of an autologous immune complex 
disorder. The suggestion is made that tubular defects could lead to 
release and subsequent sensitization to the tubular antigen, and that 
these renal tubular antigen-antibody complexes are deposited in the 
glo^uli and cause the observed lesions. Antibody to renal tubular 
antigen was detected in the serum of two subjects in this study. 
It should be emphasized that the significance of these findings is 
questionable because of the rarity of reported cases of glomerulone¬ 
phritis in patients with sickle cell disease. 
The most striking changes in renal morphology in patients with 
sickle cell disease are found in the medullary area. There is con¬ 
siderable dilatation of the vasa recta, with extravasation of blood 
into the surrounding tissue (7). Microangiographic studies have 
demonstrated amputation of the vasa recta secondary to sickling of 
red blood cells in the hypertonic medullar interstitium (11). Even 
those vessels which are present are often abnormal, being dilated, 
forming spirals, or ending bluntly. These vascular changes are 
associated with interstitial infarcts, scarring, tubular atrophy of 
varying degrees, and papillary necrosis. Similar changes have been 
reported by Mostofi, who noted foci of tubular degeneration, edema 
of the papillary stroma, and patchy interstitial fibrosis in kidneys 
removed from sickle cell patients with hematuria (l2). The papillary 
necrosis seen in patients with sickle cell disease is referred to as 
the 'medullary form" (13,1^) and is a more limited necrosis than 
traditional papillary necrosis in which the entire papilla is often 
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sloughed. This lesion is thought to be secondary to the ischemic 
vascular changes. 
Functional Changes 
Renal Plasma Flow and Glomerular Filtration Rate; Numerous studies 
performed in children with sickle cell anemia have documented an 
increase in glomerular filtration rate and total renal blood flow, 
associated with a fall in filtration fraction when compared to age- 
matched controls (l5,l6). By young adulthood (20-30 years) renal 
blood flow and GFR have returned to normal or are absolutely reduced, 
and in older patients these parameters are more often subnormal (l6). 
Thus, the published data suggest that the elevated GFR in children 
with sickle cell disease begins to decline by the second and third 
decade of life. However, the precise time course of the decline and 
its relationship to clinical activity are uncertain. In all age 
groups it has been shown that filtration fraction is decreased, i.e. 
there is a disproportionate increase in effective renal plasma flow 
in proportion to glomerular filtration rate (l6). 
The causes of the increased RPF and GFR in young patients with 
sickle cell anemia are unknown. The fact that correction of the 
anemia by prolonged transfusion of normal cells does not correct 
these abnormalitis has been interpreted to mean that the anemia per 
se is not the underlying cause (l?). Moreover, there is no apparent 
relationship between hematocrit and the GFR in the sickle cell patient 
(l8). Although the suggestion has been made that a primary increase 
in renal blood flow secondarily causes the increased GFR, this has 
not been proven. With time progressive glomerular ischemia, fibrosis 
and eventual glomerular obliteration results in the observed decline 
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in renal blood flow and GFR seen in later life. 
Urinary Concentration; Inability to maximally concentrate the urine 
is the most consistently observed and best studied renal functional 
abnormality in patients with sickle cell disease. The defect is 
present in homozygotes, patients with Hb SC, and Hb S-thal, and heter¬ 
ozygoses and appears to be related directly to the presence of sickle 
hemoglobin (4). The concentrating defect can be detected as early as 
the first year of life, and becomes progressively more severe. In 
young patients concentrating ability can be restored to normal after 
multiple blood, transfusions. However, in older patients (greater 
than 15 years) blood transfusions are ineffective in reversing the 
concentrating defect (19)• implying structured damage to the medulla. 
Patients with sickle cell disease are able to dilute their 
urine normally but are usually unable to concentrate above 700 nosm/kg. 
Maximally concentrated urine is produced by extraction of water from 
tubular fluid passing through hypertonic medullary interstitial 
tissue. Medullary hypertonicity results from reabsorption of sodiun 
chloride and urea into the renal medulla by a mechanism which de¬ 
pends on countercurrent flow of tubular fluid and blood through 
the loops of Henle and vasa recta respectively (20), Furthermore, 
the differential permeabilities of the loop of Henle and collecting 
duct are necessary for these processes to occur. 
It is believed that sodium chloride accumulation in the medul- 
lary interstitium is largely a result of active transport of chloride 
from the thick ascending loop of Henle. Hypotonic tubular fluid is 
then presented to the distal tubule and. collecting duct where water 
is reabsorbed. As fluid passes more distally the tubule becomes 
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permeable to urea, and this substance is reabsorbed from the collect¬ 
ing duct into the surrounding medullary tissue (20). Recent evidence 
suggests that reabsorption of urea into the medullary interstitium 
enables NaCl to be passively reabsorbed by the thin ascending limb 
of the loop of Henle, and that this process is necessary for con¬ 
centrating the urine above 600 mosm/kg (2l). 
Several authors have postulated that the inability of patients 
with sickle cell disease to maximally concentrate their urine is a 
result of defective NaCl reabsorption in the loop of Henle (4). 
However, under conditions of solute loading with mannitol or hyper¬ 
tonic saline, it has been shown that these patients are dble 
to increase negative free water clearance (TCH 0) appropriately with 
increasing solute loads (22). Normal TcH20 depends on NaCl reabsorp¬ 
tion from the loop with resultant water reabsorption from the collect¬ 
ing duct, and does not depend on medullary accumulation of urea (23). 
This implies that sicklers have a normal ability to reabsorb in¬ 
creasing amounts of NaCl, and that a defect in this process is not 
responsible for their inability to attain a normal, maximally con¬ 
centrated urine. 
The unique situation in sickle cell patients, i.e. inability to 
maximally concentrate their urine associated with normal TCH20 
and normal urinary dilution is most likely a consequence of the de¬ 
creased blood flow in the vasa recta (7). As previously mentioned, 
Perillie and Lpstein have shown that red blood cells containing Hb S 
become sickled when immersed in hypertonic solutions (4). A similar 
phenomen in vivo has been postulated as sickle cells enter the 
hypertonic medulla. The resulting sickling leads to increased 
blood viscosity and decreased medullary blood flow, which has been 
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by microangiographic studies (ll). The result then, is a "functional 
papillectomy' (7). Papillary ischemia results in decreased function 
or obliteration of the juxtamedullary nephrons with long thin loops 
of Henle, since it is these nephrons that populate the areas of 
abnormal blood flow (7). It appears that the juxtamedullary nerhrons 
are not necessary for elaboration of a maximally dilute urine. How¬ 
ever, since the formation of maximally concentrated urine depends 
on urea reabsorption from the collecting duct and subsequent passive 
(as well as active) NaCl transport out of the thin ascending limbs 
of these juxtamedullary nephrons, their destruction results in an 
inability to generate maximum Uosm greater than 600 mosm/Xg (2l). 
Studies in rats support this concept. Lief et al have shown that 
c 
T H^O is normal during solute loading in papillectomized rats in 
spite of a severe defect in Uosm Max (24). 
The hypothesis put forth then, is that decreased rerfusion of 
the renal papilla results in a functional papillectomy which 
is reversible by transfusion in the early stages. The loss of the 
does not interfere with the bulk reabsorption of solute 
free water, since this depends on intact functioning of the thick 
ascending loops of Henle and cortical collecting ducts in the outer 
medulla and cortex. With time, chronic ischemia of the renal papilla 
leads to irreversible damage so that transfusions will not correct 
the defect. 
Urinary Acidification; In recent years it has been found that pa¬ 
tients with sickle cell disease have an incomplete distal renal 
tubular acidosis (RTA) (25,26,27). The finding of defective urinary 
acidification is not surprising since final urine acidification takes 
place in the collecting duct, an area which is often damaged in the 
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sickle cell kidney. 
Acidification has been studied in West Indian patients by 
Goossens et al (25), and Ho ping Kong and Alleyne (26), and in Ameri¬ 
can Blacks by Oster et al (2?) using the short ammonium chloride 
acidification test (28). In the West Indian studies minimum urinary 
pH after acid loading was significantly higher and titratable acidity 
(TA) was significantly lower in patients with Hbs SS and SC, compared 
to subjects with Hbs SA and AA. NH^+ excretion did not differ among 
any of the subjects studied. A correlation between severity of the 
concentration defect and severity of the acidification defect was 
also noted. These studies demonstrate that patients with sickle 
cell disease have an "incomplete distal RTA”, that is, there is an 
inability to appropriately lower urine pH when stressed, but in the 
basal state systemic acidosis is not present, 
Ot,ter et al (27) studied 20 Black Americans with sickle cell 
disease, and compared them to patients with Hb AS and Hb AA. They 
also evaluated maximum urine to blood pCO gradients during NaHCO 
^ 3 
loading. They found that 6 of 20 patients with sickle cell disease 
vere unable to lower their urine pH to 5.3 or less after NH, Cl 
administration, and that the mean urine pH was higher than controls 
or Hb AS subjects. Hb SS subjects manifested lower excretion of TA 
and net acid in comparison to controls. There were no clinical, 
hematological, renal or acid-base differences between the Hb SS 
subjects with and without a normal response to acid loading. Their 
study also demonstrated that the bicarbonate loading test may be 
more sensitive in uncovering acidification abnormalities, since 5 
of 7 patients with sickle cell disease with normal responses to am¬ 
monium chloride had abnormal urine-blood pC02. The results of this 
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study differ somewhat from the West Indian investigations which dem¬ 
onstrated that almost every patient studied was incapable of a normal 
response to acid loading. 
It is clear that a mild form of incomplete distal RTA is present 
in many patients with sickle cell disease. Although the mechanism 
for this abnormality remains unknown, it is conceivable that it could 
result from collecting duct dysfunction secondary to the disturbances 
in papillary blood flow found in these patients. The clinical sig¬ 
nificance of this problem is not clear. Studies have shown that in 
vitro acidosis enhances the sickling of erythrocytes from patients 
with sickle cell disease (2) and several authors have reported precipi¬ 
tation of painful crises by HH. Cl or acetazolamide Induced acidosis 
(29,30). Others have also reported that metabolic acidosis is a 
major precipitating factor of painful crises (3l). However, most 
of this data stems from reports of isolated cases and further studies 
have not shown a consistent relationship between systemic acidosis 
and painful crisis. Furthermore, the observation that these patients 
are not acidemic in the basal state as a result of this defect in 
acid excretion makes it unlikely that an incomplete RTA is clinically 
significant in these patients. 
Hematuria: One of the more dramatic manifestations of sickle cell 
disease is hematuria. It is found in all persons who possess the 
gene for sickle hemoglobin, either in the homozygous or heterozygous 
state and painless, gross hematuria is a common finding (12,32). 
As discussed above, patients with sickle cell disease have reduced 
perfusion of the renal medulla, probably secondary to increased sickling 
of cells in this area ard subsequent increased blood viscosity. 
Furthermore, these patients have an overall increased renal blood 
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flovj. This combination of events — increased renal blood flow with 
reduced medullary blood flow has been offered as an explanation of 
the frequent occurrence of hematuria in these patients (7,33). 
It has been found in the rat and the dog, that efferent vessels 
from juxtamedullary glomeruli divide to form the vasa recta and 
peritubular capillaries of juxtamedullary nephrons; furthermore 
they also form the nutrient vessels for the renal pelvis. These 
latter vessels have been found to be engorged and dilated in 
patients with sickle cell disease (ll). It is suggested that engorge¬ 
ment of pelvic vessels could result from shunting of efferent 
arteriolar blood flow into pelvic mucosal capillaries thereby causing 
rupture of these vessels with subsequent hematuria (7,33). 
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BACKGROUND AND PURPOSE 
Several conclusions can be made after reviewing the literature 
on the renal complications of sickle cell disease. Many of the 
anatomical lesions in the kidneys of these patients appear to be 
the result of vascular occlusive changes, which are secondary to 
sickling of red blood cells. The most striking changes occur in 
the medullary region and correlate with the abnormalities of the 
va°a recta (11)• Characteristically, the pathologic changes consist 
of patchy interstitial fibrosis, interstitial edema, tubular atrophy, 
and papillary necrosis (12). The renal functional changes can best 
be understood when viewed in the context of these anatomical changes. 
Thus, we have seen that the sickle cell patient behaves as though 
he were "functionally papillectomized’ . (7) 
Finkelstein and Hayslett (34) have previously examined the 
contribution of medullary structures to urinary concentration and 
potassium and hydrogen ion homeostasis in rats who had undergone a 
surgical papillectomy which resulted in the loss of the terminal 
portion of the collecting ducts and interruption of loops of Henle 
of juxtamedullary nephrons. They found that papillectomized rats 
exhibited a severe urinary concentrating defect and a reduction in 
total acid excretion following ammonium chloride loading that was 
primarily due to decreased ammonium excretion. The ability to 
acidify the urine was not impaired by papillectomy. The papillect¬ 
omized animals also demonstrated a markedly impaired capacity for 
potassium (K) excretion following potassium leading. These observa¬ 
tions in the papillectomized rat (impaired concentrating and acidifying 
ability and impaired potassium excretion) are in agreement with our 
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current concepts of the function of the distal nephron. 
The surgically papillectomized rat kidney is not unlike the 
kidneys of patients with sickle cell disease in whom occlusion of 
the vasa recta from the sickling process often results in the ablation 
of the papilla. Thus, it is not surprising that patients with sickle 
cell disease exhibit defects in urinary concentration and acidifica¬ 
tion. However, no data have been reported concerning the renal 
handling of potassium or the integrity of the renin-aldosterone 
axis in these patients. Although abnormal potassium excretion has 
not been reported previously as a complication of sickle cell disease, 
such a defect has not been specifically looked for. On the basis of 
the renal histopathologic changes affecting the medullary interstitium 
such a defect in potassium excretion might be expected. Recent studies 
summarized by Giebiscn (35) have shown that greater than 90-95^ 
of the filtered potassium load is reabsorbed by the early distal 
tubule and most of the potassium appearing in the final urine is the 
result of secretion by the distal and collecting tubular cells. 
Thus, in sickle cell disease where the collecting tubules are selective¬ 
ly injured by ischemic damage to the medullary and papillary inter¬ 
stitium, one might expect an impaired ability to secrete potassium 
as has been described by Finkelstein and Hayslett in the papillect¬ 
omized rat. Such a defect may assume clinical significance in the 
sickle cell patient during crisis where intravascular hemolysis can 
acutely present an increased load of potassium to the distal nephron 
for secretion. 
Hyperkalemia and impaired renal potassium excretion has also 
been described in association with the syndrome of hyporeninism- 
hyperaldosteronism (36). This syndrome has been observed in two 
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clinical settings: patients with diabetes mellitus and patients 
with interstitial nephritis of diverse etiology (6). In the latter 
group it has been postulated that there is selective damage to the 
.juxtaglomerular apparatus with resultant hyporeninism. Thus, in 
patients with sickle cell disease one might anticipate a defect in 
potassium excretion which could be secondary to either a defect in 
the renin-aldosterone axis or to primary tubular damage. 
It was the purpose of the present study to examine tubular 
function in subjects with sickle disease with special emphasis on 
the renal tubular handling of potassium and the integrity of the 
renin-aldosterone axis. 
Methods 
Six patients with sickle cell disease (4 Hb SS, 1 Hb SG, 1 Hb S~ 
thal) were admitted to the Clinical Research Center at Yale-New 
Haven Hospital for a total of seven days per patient. Brief 
clinical histories and other pertinent laboratory data are presented 
in the appendix. Clinical and hematological data are presented in 
Table 1. Patients ranged in age from 19 to 37 years. All were 
anemic and possessed at least 50^ Hb S at the time of the study. 
Baseline renal function studies are shown in Table 2. Serum electro¬ 
lytes, BUN and creatinine were normal in all subjects. Prior to 
study all patients were placed on a three gram sodium, 2 gram potas¬ 
sium diet which was continued throughout the study period, except 
as specified below. 
Day 1: Administration of ACTH. Patients were placed at bed 
rest for one hour after which baseline bloods for plasma cortisol 
and plasma aldosterone concentrations and plasma renin activity were 

15 
drawn. ACTH (Cortrosyn) 0.25 mg was then given intramuscularly 
and repeat bloods were drawn one hour after administration. 
Day 2; Sodium Sulfate Infusion and Determination of Inulin 
and PAH Clearance. Patients remained fasted after midnight of 
Day 1 until after the NaSO^ study was completed. At 7 a.m. a small 
polyethylene catheter was inserted into one antecubital vein for 
collection of blood samples. Priming doses of inulin (40 mg/kg 
body weight) and para-aminohippurate (PAH) (l2 mg/kg body weight) 
were administered intravenously, and these were followed by sustaining 
infusions of inulin and PAH in 0.9^ sodium chloride at a rate of 0.5 
ml/min. Subjects remained supine except to void. A water diuresis 
was initiated with an oral water load (15 ml/kg) and the volume of 
each voiding was replaced by deionized water orally to maintain a 
high rate of urine flow. After a 45 minute equilibration period, 
two control urine volumes were collected. A 0.12 M solution of 
sodium sulfate (dose =1.8 mMoles/kg body weight) was then infused 
over two hours. Urines were collected every thirty to forty minutes 
for a total of six hours commencing with the initiation of the sodium 
sulfate infusion. Three bloods were drawn during the control period 
and then at one hour intervals thereafter until the end of the study. 
All bloods were analyzed for sodium, potassium, inulin, and PAH. 
Day 3: Water Deprivation Study. Patients were fasted after 
8 p.m. of the previous night. Upon arising at 7 a.m. and again at 
10 a.m. urine samples were obtained for determination of urine os¬ 
molality (Uosm). 500 mU of aqueous vasopressin was infused intra¬ 
venously from 10-11 a.m. and the next spontaneously voided urine 
(voided within 2 hours) was collected and Uosm determined. 
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Day 4; Potassium Chloride Infusion. All patients remained 
fa.sted after 12 midnight of the preceding night. At 7 a.m. catheters 
were inserted into each antecubital vein and a water diuresis was 
initiated and maintained as described in the section on sodium 
sulfate. Two control urines were collected by spontaneous voiding. 
0.?5 mEq of potassium chloride per kilogram dissolved in 400 ml of 
l/4 normal saline was then infused at a constant rate over 120 
minutes. Most patients experienced transient discomfort at the site 
of the infusion which passed within 30 minutes. Continuous electro¬ 
cardiographic monitoring revealed no changes of hyperkalemia. Two 
control bloods were obtained after 90 minutes of supine posture for 
determination of plasma aldosterone concentration and plasma renin 
activity before the KC1 infusion. Bloods for aldosterone and renin 
were subsequently obtained at 60, 120, 240, and 3&0 minutes after 
beginning the KC1 infusion. Plasma potassium, sodium and creatinine 
concentrations were determined on at least three occasions during 
the control period and every 30-60 minutes thereafter. All blood 
removed was replaced quantitatively by an equal amount of normal 
saline intravenously. Urines were collected every 30-45 minutes 
for a total of six hours starting with the potassium chloride infusion 
and analyzed for sodium, potassium, and creatinine. Patients 
remained supine except to void. 
Day 5: Ammonium Chloride Loading Study. Urinary acidifica¬ 
tion was studied using the short ammonium chloride test of Wrong and 
Davies (28). Patients were fasted after 12 midnight of the preceding 
night. At 7 a.m. a polyethylene catheter was inserted into an 
antecubital vein for blood sampling. Enough deionized water was 
administered orally to ensure voiding every 30-45 minutes. Following 
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the collection of two control urines, ammonium chloride at a dose 
of 0.1 grams/kg in gelatin capsules was given orally over 90 
minutes. All urines were then collected under mineral oil for eight 
hours and analyzed for ammonium, titratable acid, sodium, potassium 
and creatinine. Urinary pH was determined within 5 minutes of 
obtaining the specimens. Bloods for sodium, potassium, and creatinine 
were obtained during each control period and then hourly for remainder 
of the study. Venous blood was obtained during each control period 
and then at 2, 4, 6, and 8 hours after ammonium chloride for de¬ 
termination of pH, pCO^ and bicarbonate. 
Day 6: Furosemide and Volume Depletion. To determine the renal 
response to furosemide and the integrity of the renin-aldosterone 
axis, patients were first placed on a 500 mg sodium, 2 gram potassium 
diet. After obtaining two baseline urine specimens, each subject 
was given 40 mg of furosemide orally at 8 a.m. and urine specimens 
were collected individually until 3 p.m. Urine voided from 3 p.m. 
to 8 a.m. on day 7 was pooled to determine net sodium balance. 
Each sample was analyzed for sodium, potassium and creatinine. 
Bloods were obtained at 8 a.m., 11 a.m. and 1 p.m. and similarly 
analyzed. At 6 p.m, subjects were given a repeat dose of 40 mg of 
furosemide orally. Weights were obtained at 8 a.m., 6 p.m. and 8 
a.m. of day 7* At 8 a.m. on day 7» after the patients had been supine 
overnight, blood was drawn for aldosterone and renin determination. 
The patients then ambulated for 2 hours and repeat bloods for aldosterone 
and renin were drawn. At the completion of the study the subjects 
received appropriate oral salt replacement. 
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Controls 
Five healthy, age-matched volunteers studied in the same fashion 
as earlier described served as controls for the sodium sulfate and 
potassium chloride studies. Six subjects served as controls for the 
ammonium chloride study, and 9 for the furosemide study. Control 
data for urinary concentrating ability and cortrosyn study have been 
previously published. (45,46). 
Signed informed consent was obtained after care had been taken 
to explain fully to the volunteers the details of the procedures 
and any potential risks involved. No adverse effects occurred. 
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ANALYTICAL METHODS 
Urinary osmolality was determined on Advanced Osmometer Model 
3W (Advanced Instruments, Inc.) by the method of freezing point 
depression. Urinary pH was determined on an Acid-Ease Analyzer, type 
PH M 71B (Radiometer Electronic Measuring Instruments). Sodium 
and potassium were measured by flame photometry on a model IL 143 
Digital Flame Photometer (instrument Laboratory, Inc,, Lexington, 
Mass.) with an internal lithium standard. Creatinine was determined 
by a continuous flow modification of the Jaffe technique (37) • 
Titratable acidity was measured by titrating urine specimens to the 
pH of a reference buffer solution with 0.1 N NaOH. Ammonia was 
determined by the method of Conway (38). Inulin was determined by 
the anthrone method adopted for automated analysis (39) and PAH 
by the method, of Goldring and Chasis (40). 
Blood for aldosterone and plasma renin activity was collected 
in chilled syringes containing EDTA and promptly centrifuged at 4 
degrees centigrade. Plasma renin activity in blood samples were 
determined by a modification of the radioimmunoassay technique des¬ 
cribed by Haber et al (4l). Plasma aldosterone concentration was 
determined by a modification of the radioimmunoassay technique des¬ 
cribed by Bayard, et al (42), utilizing ammonium sulfate precipita¬ 
tion of bound antigen in the assay as described by Mayes, et al (43). 
CALCULATIONS 
In the statistical analysis of the data observations during 
control periods were averaged and compared with observations after 
drug administration (paired t-test). Changes in sickle cell subjects 
were compared with changes in control subjects using the Students t-test. 
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RESULTS 
Glomerular Function. There was no evidence of significant 
glomerular dysfunction in any of the sickle cell patients. None had 
proteinuria, hypertension or hematuria. The inulin clearance (C ) 
was normal or elevated in 5 out of 6 patients and mildly reduced 
in one (Table III). Normal values for C^ and CpA- in age matched 
controls are 127 and 655 respectively (l6). The mean for the 
patients with sickle cell disease was 122±13 ml/min. Renal 
plasma flow (CpAp) was normal or elevated in all 6 patients with 
sickle cell disease with a mean value of 792±77 ml/min. Filtration 
fraction ranged from 0.11 to 0.20 with a mean value of 0.l6±0.01. 
The normal value for filtration fraction in a group of age matched 
normal controls was 0.19 (l6). 
Tubular Function. Urinary Concentrating Ability: All six 
sickle cell patients had a severe urinary concentrating defect (Table 
IV). The mean Uosm after 12 hours of water deprivation was 389±13 
mosm/kg, and increased to only 422±7 mosm/kg following vasopressin 
infusion. Maximum urine osmolarity in 31 age matched controls was 
1,109±22 mosm/kg (p<0.001) after a similar period, of water depriva¬ 
tion (44). 
Ammonium chloride loading. Baseline serum bicarbonate and 
chloride concentrations and venous pH were normal in all sickle cell 
patients. Following ammonium chloride loading venous bicarbonate 
fell from 24±,47 mEq/L to 19±0.7 mEq/L in the sickle cell patients 
and from 26±0.5 mEq,/L to 20±0.5 mEq/L in the controls. Venous pH 
fell from 7.39^0.01 to 7. 34±0.01 in the patients with sickle cell 
disease and from 7.35±0.01 to 7.27±.01 in the controls (Table V). 
Urine pH fell to less than 5*3 in only one of six patients with 
sickle cell disease, with a mean decrease of the group to 5*52±.10. 
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This was significantly higher than minimum urinary pH in 6 controls 
in whom urinary pH after acid loading was 5«0±.10 (p<0.0l). In all 
of the controls urine pH fell to 5-3 or less (Table Vi). 
Maximum excretion of titratable acid in sickle cell patients 
(42± 4 yeq/min) was significantly lower than in controls (96±11 Ueq/min) 
(p<0.00l). Maximum ammonia excretion in sickle cell patients (50±8 Uea/ 
min) was also significantly less than controls (72±S yeq/min) (p<0.005). 
Net acid production was lower in the sickle cell patients (p<0.005). 
Ammonia accounted for a higher percentage of net acid production in the 
sickle cell patients compared to the controls (54±3;3 compared to 
42±2^°, p<0.02) (Table VI). When ammonia excretion was plotted 
against urine pH, the individual values for the sickle cell patients 
were lower than those of controls, indicating that the lower values 
for ammonia excretion in sickle cell patients could not be attributed 
to higher urinary pH. 
Figures 1-3 illustrate pH, titratable acid and ammonia excretion 
during ana after acid loading. The values for each of the sickle 
cell patients are plotted individually, and the range of the values 
for the controls is shown by the shaded area. There was no overlap 
in titratable acid excretion between the two groups during the entire 
study. Urine pH was significantly different between the two groups 
from hours two through six of the study (p<.Ol). The differences 
in ammonia excretion, while not as marked as with titratable acid, 
persisted throughout the study. 
Sulfate Infusion. The response to sodium sulfate infusion 
was markedly impaired in all sickle cell patients (Figure 4, Table VII), 
Baseline urinary potassium excretion in the sickle cell group 

22 
(37±5 ueq/min) was significantly lower (p<0,0l) than in controls 
(91*4 Heq/min). The maximum increment in potassium excretion above 
baseline in sickle cell patients (20±4 yeq/min) was also significantly 
less than in controls (107*20 yeq/min) (p<0.OOl). 
In figure 4 the individual values for potassium excretion (U V) 
are plotted for the six hour time period beginning with the start 
of the sodium sulfate infusion. The sickle cell patients demonstrated 
only a very slight increase in U^V in response to sodium sulfate in 
contrast to the controls, in whom potassium excretion reached a 
maximum at ijr hours after the infusion was begun. The differences 
in potassium excretion between the two groups are highly significant 
at each individual time point (p^O.Ol). 
The increase in sodium excretion followi-g sodium sulfate was 
similar in controls and sickle cell patients. Both groups reached 
a peak U^. V of approximately 800 yeq/min two hours after the infusion 
was begun and in both sodium excretion returned to baseline by the 
end of six hours. 
There was no difference in plasma potassium or sodium concen¬ 
trations between the two groups at any time during the study. 
Potassium Chloride Infusion. Baseline potassium excretion was 
lower in the sickle cell patients (33*4 yeq/min) compared to controls 
(77*15 yeq/min) (p<0.0l). Baseline plasma potassium concentrations 
were similar in the two groups. The maximum increase in potassium 
excretion following potassium chloride loading was significantly 
lower in the sickle cell group than in the controls (ll4±l4 yeq/min 
compared to 353*41 yeq/min? p<0.OOl). The percent of the potassium 
load excreted over the five hour experimental period was 28±5% in 
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the sickle cell patients compared to 6l±7/0 in the controls (p<0.0l). 
Table VI, Figure 5 is a plot of the urinary potassium excretion 
during and after the potassium chloride infusion. Although the 
sickle cell patients demonstrated some increase in U.,V above base- 
k 
line, compared to the controls the response is markedly impaired. 
Despite the marked impairment in potassium excretion observed 
in the sickle cell patients, the increase in plasma potassium con¬ 
centration was similar in both groups. Figure 6 shows there was no 
difference in the plasma potassium concentrations between sickle 
cell patients and controls at anytime during the potassium chloride 
study. 
and Volume Depletion. Baseline potassium and sodium 
excretion were not significantly different between the sickle cell 
patients and the controls. Maximum potassium excretion after furo- 
semide was 99±13 yeq/min in the sickle cell patients and 203±20 eq/min 
in the controls (p<0.00l) (Table IX). In figure 7 the values of 
V for each sickle cell patient are displayed. The normal control 
range is shown by the shaded area. Potassium excretion increased 
dramatically in the controls with peak excretion occurring by the 
end of the third hour. Only two sickle cell patients (RB and LC) 
increased U^V to the same range as the controls. 
Sodium excretion followed a similar pattern to that observed 
with potassium excretion (Table IX, Figure 8). Five out of six 
sickle cell patients demonstrated a blunted natriuretic response to 
furosemide but a statistically significant difference was not 
achieved because of the exaggerated natriuretic response of patient 
RB. When this patient is omitted the peak V was significantly 
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less than controls (p<0,00l). 
Plasma aldosterone and plasma renin activity were determined at 
the end of this part of the study to evaluate their response to volume 
depletion. Table X compares baseline plasma renin activity and 
plasma aldosterone concentration before and after volume depletion 
in the sickle cell patients. There was a significant increase in 
plasma aldosterone from 9,1±84 ng/lOO ml to 24.3±5 ng/lOO ml with 
volume depletion and a further increase to 78*30 ng/lOO ml was 
achieved after two hours of ambulation. Plasma renin activity in¬ 
creased similarly from .74 ng/ml of angiotension II generated per 
hour to 6.75*1.9 ng/ml/hr and then to 14.08+4.3 ng/ml/hr. These 
results are similar to values previously reported by us in healthy 
controls (62). 
Mjlini strati on of AGTH (Cortrosyn). The results of administra¬ 
tion of synthetic AGlH to the sickle cell patients are shown in 
Table XI. All patients demonstrated an increase in plasma cortisol 
and plasma aldosterone in response to cortrosyn. Plasma aldosterone 
rose from a mean value of 10.7±1.5 ng/lOO ml to 36.5±18 ng/lOO ml. 
Plasma cortisol rose from a mean value of 11,5±1.4 pg/lOO ml to 
25*7.7 Mg/100 ml. The mean increment in plasma aldosterone was 3.2 
fold, while that for cortisol was 2.2 fold. These results are in 
agreement with reports in the literature of normal subjects in whom 
plasma aldosterone rose 3.4 fold and pla,sma cortisol rose 2.8 fold 
in response to similar doses of synthetic AGTH (45,46). 
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DISCUSSION 
This study documents the presence of severe tubular dysfunction 
in patients with sickle cell disease despite normal or elevated 
glomerular filtration rate and renal plasma flow. All six patients 
studied manifested a severe defect in urinary concentrating ability 
that was resistent to administration of exogenous vasouressin. 
Abnormal urinary acidification was also observed in all six sickle 
cell patients following ammonium chloride administration. Five out 
of six patients were unable to lower their urine pH to less than 5.3 
and all six patients demonstrated a blunted maximum increase in 
urinary excretion of titrataole acid and ammonia. Since serum chloride 
and bicarbonate concentrations and venous pH were normal in all, 
these patients can be assumed to have an incomplete distal renal 
tubular acidosis. Other authors who have previously examined urinary 
acidification in patients with sickle cell disease (25,26,27) have 
also reported higher urinary pH and lower titratable acid excretion 
in sickle cell patients after ammonium chloride. However, none of 
these previous studies have reported significantly lower ammonia 
excretion in sickle cell patients when corrected for urinary pH. 
In patients with incomplete renal tubular acidosis (RTA) ammonium 
characteristically constitutes a greater than normal fraction of 
urinary acid both before and during induced acidosis (47). In our 
patients ammonia also represented a greater fraction of total 
acid produced but absolute excretion was lower than that observed 
in controls. The finding of diminished ammonia excretion, even 
after correction for urine pH, is in contrast to other reported 
cases of incomplete RTA, where ammonia excretion is normal or in- 
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creased (28,47). The decrease in NH^+excretion is, however, 
consistent with previously described histopathologic changes in 
sickle cell patients where renal medullary and papillary ischemia 
results in interstitial scarring and tubular atrophy with varying 
degrees of distal and collecting tubular dysfunction. Since ammonia 
excretion and final acidification occur primarily in the collecting 
tubules (20), the incomplete RTA seen in these patients is not 
unexpected. Since maximum urinary concentration is also dependent 
upon normal collecting duct and loop of Henle function, and since 
these structures are selectively injured in the sickle cell kidney, 
it is not surprising that these patients also demonstrate a severe 
vasopressin-resistant defect in concentrating ability. 
All of our patients with sickle cell disease demonstrated ab¬ 
normal urinary potassium excretion in response to intravenous sodium 
sulfate and potassium chloride, as well as to oral furosemide. 
Renal potassium handling has not previously been examined in 
patients with sickle cell disease. However, since potassium ex¬ 
cretion primarily reflects secretion in the distal nephron (distal 
tubule and collecting duct) (35), impairment of this aspect of tubular 
function might be expected in sickle cell patients. 
Potassium secretion by the distal and collecting tubules is 
thought to be a passive process, with potassium diffusing from a 
region of high concentration (intracellular potassium is maintained 
at a high level by an active pump located on the pericapillary side 
of the distal and collecting tubular cells (35) (Figure 9, step l). 
The passive diffusion of potassium from cell to lumen is also favored 
by the electrical gradient, lumen 50 millivolts negative with respect 
to cell (49) (step 2). The presence of adequate amounts of sodium 
in the distal and collecting tubular fluid is responsible for the 
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generation of the electromotive force that drives potassium from 
tubular cell to lumen (50). Since sodium permeability is greater 
than that of chloride, reabsorption of sodium causes the lumen to 
become slightly electronegative, and this in turn serves as a 
driving force for potassium secretion (step 3)» The transcellular 
movement of potassium from pericapillary to lumenal side in exchange 
for sodium is also strongly modulated by aldosterone (51). 
Defective potassium excretion could, therefore, be the result 
of decreased delivery of sodium to the distal nephron, a defect in 
aldosterone secretion, or a primary defect in tubular secretion of 
potassium. Differences in sodium delivery to distal sodium-potassium 
exchange sites cannot account for the impairment in urinary potas¬ 
sium excretion observed in our sickle cell patients. During the 
seven day balance period when dietary intake of sodium and potassium 
remained constant, daily urine sodium excretion remained in the 
normal range, following both sodium sulfate and potassium chloride 
infusions, sodium excretion rose similarly in both control and sickle 
cell groups, yet urinary potassium was markedly decreased in the 
latter. 
It is well known that aldosterone modulates potassium excretion 
by the kidney (51,52). Impaired potassium secretion with resulting 
hyperkalemia has frequently been recognized as secondary to hypo- 
aldosteronism, and hyperaldosteronism is associated with excessive 
urinary losses of potassium (53)« The effect of aldosterone on 
potassium transport is probably independent of its effect on sodium 
excretion - Williamson, et al have shown that if adrenalectomized 
rats are treated with Dactinomycin (to prevent RNA synthesis), 

28 
the sodium reabsorption response of aldosterone is blocked, but the 
kaliuretic Effect is intact (54,55). Several reports have appeared 
in the literature attributing the development of hyperkalemia and 
decreased potassium excretion in patients with renal disease to 
the syndrome of hyporeninemic-hypoaldosteronism (56,57). The mech¬ 
anism for this specific defect is not known, however, it has been 
suggested that an abnormality of renin production may be the result 
of damage to the juxta-glomerular apparatus acquired during the 
course of the renal disease (56). 
Because of the important role of aldosterone in renal potassium 
handling we attempted to determine whether the impairment in potassium 
excretion observed in the sickle cell group could be attributed to 
a defect in the renin-aldosterone axis. Such a defect might be 
expected because of the known association of hypoaldosteronism and 
renal diseases resulting from interstitial damage. 
Previous studies have shown that acute administration of AGTH 
is a potent stimulus to both cortisol and aldosterone secretion (45). 
The plasma cortisol and aldosterone responses to cortrosyn in all 
six sickle cell patients were similar to values previously reported 
in the literature for control subjects (45,46). The integrity of 
the renin-aldosterone axis was also examined following volume de¬ 
pletion, a potent stimulus to aldosterone secretion. A normal in¬ 
crease in both plasma renin activity and plasma aldosterone con¬ 
centration was observed. These results demonstrate a normally 
functioning renin-aldosterone axis in sickle cell patients and exclude 
hypoaldosteronism as the cause of the impaired potassium excretion. 
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Defective tubular secretion of potassium in the absence of 
significant renal impairment or hypoaldosteronism has only rarely 
been reported (57»58» 59,60,62). Healy et al (6l) described the 
first such case of unexplained hyperkalemia in a young boy with normal 
adfcenal and renal function but with an inability to augment renal 
potassium excretion in response to flourohydrocortisone, sodium 
sulfate, or acetazolamide, all of which are known to markedly en¬ 
hance renal tubular potassium secretion. Subsequently, three more 
case reports have appeared describing a similar tubular defect in 
potassium excretion (57*58,60). To examine this possibility in 
sickle cell patients all subjects received a standard sodium sulfate 
infusion. This is known to directly enhance tubular secretion of 
potassium by enhancing delivery of sodium to the distal sodium- 
potassium exchange sites, while at the same time increasing the 
lumenal negativity because of the impermeant sulfate anion. Despite 
a similar increase in sodium excretion the increase in potassium 
excretion in sickle cell patients was markedly blunted, suggesting 
a primary defect in tubular secretion of potassium. Most recently 
DeFronzo et al have documented a similar defect in patients with 
systemic lupus erythematosis (SLE) (62). Since other investigators 
have shown that many patients with SLE have a prominent interstitial 
nephritis that is associated with the deposition of antibodies in 
the tubular basement membranes and. the surrounding interstitium 
(63,64), it is interesting to speculate that the hyperkalemia is 
the consequence of tubular dysfunction secondary to these immune 
globulin deposits. Since sickle cell )atients have also been shown 
to have s. prominent interstitial nephritis, it is possible that a 
similar immunologic process is present. 

30 
Our patients also demonstrated marked impairment in renal potas¬ 
sium excretion in response to an acute potassium load and to furose- 
mide. ihe latter is known to enhance potassium excretion by providing 
more sodium to the distal sodium—potassium exchange sites and by 
causing volume depletion with concomitant stimulation of aldosterone 
secretion (65). Since the aldosterone response to furosemide was 
normal in sickle cell patients, the blunted kaliuretic response 
cannot be explained on this basis. Although it would appear that 
this blunted response is further evidence for a tubular defect 
our data also demonstrated a blunted natriuretic response to 
furosemide in sickle cell patients. Therefore, the impaired 
response of UKV post furosemide in the sickle cell patients could 
be partially explained by the decreased delivery of sodium to the 
distal potassium exchange sites. 
Although patients with sickle cell disease manifest a defect 
in renal potassium excretion, hypsrkalemia is conspicuously absent. 
During the potassium chloride infusion, the sickle cell patients 
excreted only 25H of the potassium load within five hours compared 
to 6l% in the controls, yet plasma potassium rose similarly in both 
groups. ihese results strongly suggest the presence of an extrarenal 
mechanism, either acute or chronic, of potassium adaptation in the 
sickle cell group. A similar mechanism of potassium adaptation has 
been postulated in patients with chronic renal failure who have been 
shown to excrete significantly more potassium in their stool than 
normals (66). 
Other authors have suggested that extrarenal adaptation results 
from the translocation of potassium from extracellular to intracellular 
compartments. Alexander and Levinsky reported lower plasma potassium 
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in rats treated with a high potassium diet following an acute potas¬ 
sium load (67). Since lower plasma potassium levels in the rats 
on the high potassium diet could not be explained by increased renal 
potassium excretion, these authors concluded that enhanced tissue 
uptake of potassium was responsible for the potassium adaptation. 
Furthermore, they demonstrated that potassium adaptation was lost 
following adrenalectomy and could be restored following mineralo- 
corticoid replacement. Although the aldosterone response to volume 
contraction and cortrosyn was normal in our sickle cell patients, 
our data do not exclude enhanced extrarenal tissue sensitivity to 
aldosterone. Our data also do not define the relative contributions 
of enhanced gastrointestinal secretion versus increased cellular 
(liver, muscle, etc.) uptake of potassium following intravenous 
potassium chloride administration. However, it seems unlikely that 
increased cellular uptake of potassium could be playing a primary 
role in chronic potassium adaptation, since eventually cellular 
sites of potassium sequestration would become saturated and hyper¬ 
kalemia would ensue. Since renal potassium excretion is low, it 
must be assumed that these sickle cell patients have augmented 
gastrointestinal potassium losses. 
Evidence has also accumulated implicating insulin in the extra- 
renal mechanism responsible for modulating serum potassium levels 
(68,69). Acute hyperkalemia stimulates insulin release, which in 
turn blunts the rise in serum potassium concentration by enhancing 
cellular uptake of potassium (70). 
In summary, then, our data show that in response to KG1 
infusion patients with sickle cell disease excrete less potassium 
in the urine compared to controls, yet their plasma potassium levels 
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are similar. In order to determine whether these patients have 
developed chronic adaptive mechanisms for eliminating potassium 
(e.g. G.I. losses), or whether the infused potassium is transferred 
acutely into the intracellular compartment (mediated by insulin) 
further investigations must be carried out. These include balance 
studies to compare daily urinary potassium excretion in sickle cell 
patients with controls, as well as measurement of fecal potassium 
losses. 
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CONCLUSION 
The results of the present study demonstrate severe distal and 
collecting tubular dysfunction in patients with sickle cell disease 
despite normal preservation of glomerular function. All sickle cell 
patients displayed impaired concentrating and acidifying ability 
and decreased ability to excrete potassium in response to a variety 
of stimuli known to enhance potassium excretion. The defect in 
potassium excretion could not be explained by hypoaldosteronism or 
decreased distal sodium delivery. Despite the impairment in renal 
potassium excretion, hyperkalemia was not present suggesting an extra- 
renal mechanism of potassium adaptation. 
It is likely that the defects in tubular function in these pa¬ 
tients result from the sickling of red blood cells within the vasa 
rectae with resultant thrombosis and disruption of the microvas¬ 
culature. The eventual result is fibrosis which is most pronounced 
in the medullary and papillary areas. The tubular damage results in 
a "functionally papillectomized" kidney, characterized by impaired 
concentrating ability, urinary acidification and potassium excretion. 
Although impairment in potassium excretion does not present an 
immediate clinical problem, it is likely that with time progressive 
renal damage may ultimately predispose to clinically significant 
hyperkalemia. Finally, the results of this study suggest that the 
sickle cell kidney may be viewed as a model for other forms of 
interstitial nephritis, in which impaired urinary concentrating 
ability, renal tubular acidosis, and hyperkalemia are important 
physiologic features. 
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TABLE VII 
RENAL RESPONSE TO NaSO. 
4 INFUSION 
Basal Maximum 
Lvv V (pEn/min 
Sicklers: 
(pEq/min) 
ED 43 59 
RB 47 58 
JG 42 82 
SE 43 60 
LC 34 53 
AE 15 30 
Mean ±SEM 3715 5715 
Controls: 
A 
B 
C 
D 
E 
130 
68 
92 
115 
51 
91±15 
p<0.01 
282 
199 
223 
170 
116 
198120 
p<0.01 
Mean ±SEM 
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LEGEND FOR FIGURES 
Figures 1, 2, and 3. Urine pH, titratable acid excretion and am¬ 
monia excretion are plotted during the ammonium chloride study. 
The values for each of the sickle cell patients are plotted 
individually and the range of the controls is shaded. 
Figure 4. Urinary potassium excretion (U V) is plotted during the 
NaSO^ infusion. The solid circles connected by solid lines 
(©-©) represent the curves for the individual sickle cell 
patients. The open circles connected by broken lines (o-o) 
represent individual curves for the control subjects. 
Figure 5. Urinary potassium excretion (U V) is plotted during the 
KC1 infusion. The values for individual sickle cell patients 
are represented by solid circles and solid lines. The control 
subjects are represented by open circles and broken lines. 
Figure 6. The values for plasma potassium are plotted during the 
KG1 infusion. The mean values and the S.E.M. for the control 
period, and for subsequent hourly intervals are plotted for 
the sickle cell patients (solid circles, solid line) and the 
controls (open circles, broken lines). 
Figure 7. Urinary potassium excret ion (UKV) is plotted during the 
furosemide study. The values for each of the sickle cell patients 
are represented by solid black circles connected by solid lines. 
The range of the control values is shaded. 
Figure 8. Urinary sodium excretion (U V) is plotted during the 
furosemide study. The values for each of the sicklers are 
represented by solid black circles connected by solid lines. The 
range of the control values is shaded. 
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Minutes 

53 
3000 
m i n 
2000 
100 0 
120 240 
—1 
3 6 ( 
Minutes 

DISTAL TUBULAR CELL 
LUMEN PERITUBULAR 
fluid 
N a 
Figure IX: Schematic representation of potassium secretion bv the distal 
tubular cell (see text). 
Step 1: Intracellular potassium is maintained at a high level bv an 
active pump located on the pericapi]larv side of the distal and 
collecting tubular cells. 
Step'2: The passive diffusion of potassium from cell to lumen is also 
favored by the electrical gradient, lumen 50 millivolts negative 
with respect to cell. 
Step 3: Since sodium permeability is greater than that of chloride, re¬ 
absorption of sodium causes the lumen to become slightlv electroneg¬ 
ative, and this in turn serves as a driving force for potassium 
secretion. 
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APPENDIX 
Case Histories 
ED: This 22 year old black male was first diagnosed as having lib SS when 
he presented at age 3 with a pneumococcal pneumonia. Since that time he 
has had approximately seven episodes of pneumonia responding favorably 
to antibiotics. During his childhood and early adolescence the patient 
had approximately one painful crisis every three years. In the last year 
he has had 5 painful crises characterized by severe joint, abdomen, and 
chest pain, and has been hospitalized on 3 occasions. From age 3-9 
years he received periodic transfusions to maintain his hemotocrit above 
30 volumes percent and over the last year a similar transfusion regimen 
was reinstituted. His course has been complicated by recurrent bilateral 
medial malleoli ulcers treated with skin grafts. In 1975 the patient was 
noted to have cholelithiasis which was treated with cholecvstectomv. 
There is no clinical history of cardiac or renal disease. On physical 
examination the blood pressure was 115/80 mm Hg, pulse 65 per minute, 
and respirations 14 per minute. The lungs were clear to auscultation and 
percussion. Examination of the heart revealed a II/VI systolic ejection 
murmur at the apex. Abdominal exam was unremarkable except for an old 
cholecystectomy scar; there was no organomegaly or tenderness. The 
extremities revealed healing ulcers over both medial malleoli. The re¬ 
mainder of the physical examination was within normal limits. Admission 
laboratory values included: hematocrit 30% with 65% Hh S (one week post 
3 
transfusion); white blood cells 12,700/mm ; and reticulocyte count 14%. 
Urinalysis revealed no protein, glucose, ketones, or cellular elements. 
Serum uric acid was 7.2 mg/100 ml. Serum electrolytes, blood urea 
nitrogen, creatinine, and inulin clearance are given in Tables I and II. 
Chest x-ray showed an enlarged heart with increased pulmonary flow. 
Electrocardiogram demonstrated left ventricular hypertrophy. 
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RB: This 27 year old black female was diagnosed as having HB SC at age 
7 when she was evaluated for recurrent episodes of bone pain. She con¬ 
tinues to have 1 to 3 attacks per month but these rarely result in hosp¬ 
italization. She has not received any blood transfusions for the last 
seven years and she has never had skin ulcers, pneumonia, or clinical 
evidence of cardiac or renal disease. On physical examination the blood 
pressure was 120/90 mm Hg, the pulse 80 per minute, and respirations 16 
per minute. Cardiopulmonary exam was within normal limits. The ab¬ 
domen was non tender and there was no organomegaly. The remainder of 
the physical examination was within normal limits. Admission laboratory 
a 
values were: hematocrit 32% with 50% Hb S; white blood cells 10,700/mm ; 
and reticulocyte count 4%. Urinalysis revealed no protein, glucose or 
ketones, and 4-6 white blood cells per high power field. Serum uric 
acid was 5.1 mg/100 ml; and serum electrolytes, blood urea nitrogen, 
creatinine, and inulin clearance are given in Tables I and II. Chest 
x-ray revealed normal heart size, clear lung fields, and bony changes 
consistent with sickle cell disease. Electrocardiogram was within normal 
limits. 
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JG: This 36 year old black female was diagnosed as having Hb SS at age 
22 during a routine evaluation for normal pregnancy. Her clinical course 
was unremarkable with only a few painful crises over the next 10 years, 
until 1972 when she presented with fever, weight loss, cough, and dyspnea 
on exertion. Chest x-ray revealed hilar adenopathy and conjunctival 
biopsy confirmed the diagnosis of sarcoid. The patient was treated with 
a short course of prednisone with complete resolution of her clinical symp¬ 
toms and chest x-ray. Renal evaluation at this time revealed a normal 
serum creatinine and urinalysis. Since 1972 the patient has had approxi¬ 
mately 4 painful crises per year characterized by abdominal, chest and 
joint pain and in 1974 she was placed on a hvpertransfusion regimen, 
receiving 2 units of packed red blood cells every month. There is no 
history of recurrent infection, skin ulcers, or cardiac disease. Current 
medications include prednisone, 12.5 mg every day. On physical examina¬ 
tion the blood pressure was 110/60 mm Hg, pulse 60 per minute, and respira¬ 
tions 14 per minute. The lung fields were clear to percussion and ausculata- 
tion. The cardiac exam revealed a soft S^ at the left sternal border and 
a 2/6 systolic ejection murmur at the left sternal border. The spleen 
was not palpable. The remainder of the physical examination was within 
normal limits. Admission laboratory values were: hematocrit 29% with 
3 
52% Hb S; white blood cells 14,200/mm ; and reticulocyte count 9%. Urin¬ 
alysis revealed no protein, glucose, ketones, or cellular elements. Serum 
uric acid was 2.5 mg/100 ml. Chest x-rav revealed clear lung fields and 
a prominent left ventricle. Electrocardiogram was within normal limits. 
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SE: This 26 year old black female was diagnosed as having Hb SS at the 
age of 15 months when she presented with swollen, tender lower extremities. 
Since that time the patient's clinical course has been relatively benign 
with only 3 hospitalizations for painful crisis and one for pneumonia. 
In 1971 the patient became pregnant and was placed on a hvpertransfusion 
regimen. However, she has not received any blood transfusions since 
her pregnancy in 1971. There is no clinical history of cardiac or renal 
disease. On physical examination the blood pressure was 124/72 mm Hg, the 
pulse was 88 per minute, and respirations 14 per minute. Physical examin¬ 
ation was within normal limits. Admission laboratory values were: 
a 
hematocrit 19% with 91% Hb S; white blood cells 12,5fl0/mm , and reticulo¬ 
cyte count 17.2%. Urinalysis revealed no protein, glucose, ketones, or 
cellular elements. Serum uric acid was 4.3 mg/100 ml. Serum electro¬ 
lytes, blood urea nitrogen, creatinine, and inulin clearance are given 
in Tables I and II. Chest x-ray was unremarkable except for bony changes 
in the vertebral bodies consistent with sickle cell disease. The electro¬ 
cardiogram was within normal limits. 
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LC: This 21 year old black male was diagnosed as having Hb 88 in early 
childhood when he presented with painful bone crisis and leg ulcers. 8ince 
this time he has had approximately 2-4 hospital admissions per year for 
painful crisis and was treated with blood transfusions on most of these 
occasions. Over the last two years he has noted mild dyspnea on exertion. 
There is no history of pneumonia, leg ulcers, or renal dysfunction. On 
physical examination the blood pressure was 110/60 mm Hg, pulse 70 per 
minute, and respirations 16 per minute. Examination of the eyes revealed 
mild scleral icterus. There were diffuse rhonchi heard during Inspira¬ 
tion and expiration throughout both lung fields. The heart sounds were 
normal and no murmurs were present. The liver span was 14 cm; the spleen 
was not palpated. The remainder of the physical examination was within 
normal limits. Admission laboratory values were hematocrit 25% with 73% Hb S 
3 
white blood cells 12,400/mm ; and reticulocyte count Q%. Urinalysis re¬ 
vealed no protein, glucose, ketones, or cellular elements. Serum, electro¬ 
lytes, blood urea nitrogen creatinine and inulin clearance are given in 
tables I and II. Serum bilirubin was 0.25 mg/100 ml indirect, and 4.0 mg/ 
100 ml total and liver function tests were all normal. Chest x-ray showed 
mild cardiomegalv and bony changes consistent with sickle cell disease. 
Electrocardiogram was within normal limits. 
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AE: This 19 year old black female was first diagnosed as having Hb S-thal 
at birth. She was hospitalized only once as a child for a painful bone 
crisis. Over the last 5 years she has had frequent (3-4 per month) 
episodes of joint and bone pain which she treats at home with bed rest, 
tylenol, and fluids. In the last two years the patient has been hospitalized 
on two occasions for gross hematuria and bacteriuria. On both occassions 
the hematuria resolved with fluids and antibiotics. She has not had any 
further episodes of hematuria, urinary tract Infection, pyuria, or 
bacteriuria. She has only been transfused on one occasion. There is 
no history of leg ulcers, pneumonia, or cardiac disease. On physical 
examination the blood pressure was 114/70 mm Hg, pulse 80 per minute, and 
respirations 16 per minute. Cardiac exam revealed a grade II/VI systolic 
ejection murmur at the lower left sternal border. On abdominal exam the 
spleen was palpated 2.5 cm below the left costal margin. The liver was 
not enlarged. The remainder of the physical examination was within 
normal limits. Admission laboratory values were hematocrit 25% with 66% 
Hb S; white blood cells 6,500/mm , and reticulocyte count 23%. Urinalysis 
revealed no protein, glucose ketones, or cellular elements. Uric acid 
was 6.5 mg/100 ml. Serum electrolytes, blood urea nitrogen, creatinine, 
and inulin clearance are given in Tables I and II. Chest x-ray was normal. 
Electrocardiogram revealed Inverted T waves in the precordial leads. An 
intravenous pyelogram done on this admission was entirely normal. 
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